Tatva Chintan Pharma

₹1155 -10.6 | 0.9%

WEBSITE BSE:543321 NSE : TATVA 10 May, 16:01

Market Cap ₹2702 Cr.

Stock P/E 87.5

P/B 3.7

Current Price ₹1155

Book Value ₹ 315.1

Face Value 10

52W High ₹1888.1

Dividend Yield 0.17%

52W Low ₹ 1063.4

Edit Ratio

Tatva Chintan Pharma Research see more...

Overview Inc. Year: 1996Industry: Chemicals

Tatva Chintan Pharma Chem Ltd manufactures and sells chemical substances in India. The employer offers a portfolio of structure directing retailers for zeolites synthesis; phase transfer catalysts; electrolyte salts for super capacitor batteries; and pharmaceutical APIs, agrochemical products, and different chemical substances in the form of intermediates, disinfectants, catalysts, and solvents. It also provides quaternary compounds and quats, and bulk tablets, in addition to trading of speciality chemical substances. It serves diverse industries, together with the petroleum, pharmaceutical, agro-chemicals, automotive, paints and coatings, dyes and pigments, personal care, and flavour and fragrances industries. The corporation additionally exports its merchandise to about 25 countries. Tatva Chintan Pharma Chem Ltd was incorporated in 1996 and is established in Vadodara, India.

Tatva Chintan Pharma Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Tatva Chintan Pharma Quarterly Results

#(Fig in Cr.)	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Net Sales	105	99	88	90	121	125	114	97	84	98
Other Income	5	0	2	2	1	1	1	1	1	5
Total Income	109	99	90	92	122	125	115	97	85	103
Total Expenditure	81	77	73	79	103	108	93	76	73	83
Operating Profit	29	22	17	13	19	17	22	21	12	20
Interest	1	1	1	2	2	3	3	3	0	0
Depreciation	2	2	2	2	2	3	6	7	7	6
Exceptional Income / Expenses	0	0	0	0	0	-4	0	0	0	0
Profit Before Tax	25	19	14	9	14	8	13	11	5	14
Provision for Tax	3	1	4	2	3	-9	4	3	2	4
Profit After Tax	23	18	10	7	12	17	10	8	3	10
Adjustments	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	23	18	10	7	12	17	10	8	3	10
Adjusted Earnings Per Share	10.3	7.9	4.4	3.2	5.2	7.6	4.3	3.3	1.5	4.1

Tatva Chintan Pharma Profit & Loss

#(Fig in Cr.)	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	135	206	263	300	434	424	393
Other Income	5	0	1	5	9	6	8
Total Income	140	207	265	306	443	429	400
Total Expenditure	114	172	208	234	325	363	325
Operating Profit	26	35	57	72	118	67	75
Interest	3	4	4	4	5	9	6
Depreciation	4	4	5	7	8	10	26
Exceptional Income / Expenses	-0	1	0	0	0	-4	0
Profit Before Tax	20	27	48	61	104	45	43
Provision for Tax	7	7	10	8	8	-1	13
Profit After Tax	13	21	38	52	96	45	31
Adjustments	0	0	0	0	0	0	0
Profit After Adjustments	13	21	38	52	96	45	31
Adjusted Earnings Per Share	6.5	10.2	18.8	26	43.3	20.5	13.2

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	-2%	17%	26%	0%
Operating Profit CAGR	-43%	6%	21%	0%
PAT CAGR	-53%	6%	28%	0%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	-30%	NA%	NA%	NA%
ROE Average	9%	25%	29%	27%
ROCE Average	8%	21%	23%	22%

Tatva Chintan Pharma Balance Sheet

#(Fig in Cr.)	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	62	80	118	166	473	515
Minority's Interest	0	0	0	0	0	0
Borrowings	20	32	39	27	13	4
Other Non-Current Liabilities	2	4	5	4	-8	-11
Total Current Liabilities	63	73	88	128	171	236
Total Liabilities	147	188	249	325	649	744
Fixed Assets	56	67	111	120	160	196
Other Non-Current Assets	11	6	5	10	54	234
Total Current Assets	80	114	133	195	436	314
Total Assets	147	188	249	325	649	744

Tatva Chintan Pharma Cash Flow

#(Fig in Cr.)	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	8	16	10	4	63
Cash Flow from Operating Activities	7	25	20	20	28
Cash Flow from Investing Activities	-17	-40	-21	-197	-101
Cash Flow from Financing Activities	17	10	-5	235	38
Net Cash Inflow / Outflow	8	-5	-6	59	-36
Closing Cash & Cash Equivalent	16	11	4	63	27

Tatva Chintan Pharma Ratios

#	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	6.47	10.23	18.81	26.02	43.25	20.52
CEPS(Rs)	8.26	12.23	21.2	29.37	46.95	24.83
DPS(Rs)	0	0	0	5	2	2
Book NAV/Share(Rs)	30.97	39.68	58.59	82.62	213.44	232.25
Core EBITDA Margin(%)	15.87	16.54	21	22.17	25.01	14.34
EBIT Margin(%)	16.73	15.19	19.7	21.66	25.2	12.59
Pre Tax Margin(%)	14.4	13.28	18.08	20.18	24	10.57
PAT Margin (%)	9.6	9.96	14.36	17.38	22.1	10.73
Cash Profit Margin (%)	12.24	11.91	16.18	19.62	23.98	12.99
ROA(%)	8.83	12.28	17.32	18.21	19.68	6.53
ROE(%)	20.9	28.95	38.29	36.85	30.01	9.21
ROCE(%)	19.15	22.78	28.4	28.04	25.75	8.35
Receivable days	85.31	64.5	62.97	85.15	61.98	60.72
Inventory Days	79.46	57.57	68.74	82.27	101.78	143.16
Payable days	127.87	74.8	73.88	94.96	86.25	61.91
PER(x)	0	0	0	0	53.35	81.23
Price/Book(x)	0	0	0	0	10.81	7.18
Dividend Yield(%)	0	0	0	0	0.09	0.12
EV/Net Sales(x)	0.41	0.34	0.33	0.35	11.66	9.02
EV/Core EBITDA(x)	2.12	2.01	1.55	1.46	43.03	57.43
Net Sales Growth(%)	0	52.3	27.6	14.1	44.38	-2.31
EBIT Growth(%)	0	38.26	65.49	25.6	67.87	-51.19
PAT Growth(%)	0	58.03	83.95	38.3	83.45	-52.56
EPS Growth(%)	0	58.03	83.95	38.3	66.26	-52.56
Debt/Equity(x)	0.9	0.97	0.77	0.54	0.25	0.33
Current Ratio(x)	1.28	1.57	1.51	1.52	2.54	1.33
Quick Ratio(x)	0.81	1.08	0.79	0.95	1.55	0.64
Interest Cover(x)	7.18	7.94	12.15	14.65	20.9	6.21
Total Debt/Mcap(x)	0	0	0	0	0.02	0.05

Tatva Chintan Pharma Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	79.17	79.17	79.17	79.17	79.17	79.17	79.17	72.02	72.02	72.02
FII	2.91	3.05	3.53	3.59	3.74	3.54	3.19	4.41	4.21	3.65
DII	7.87	8.13	10.76	11.16	11.52	11.71	11.07	13.79	13.06	12.84
Public	10.05	9.65	6.55	6.08	5.57	5.58	6.56	9.78	10.71	11.49
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	1.75	1.75	1.75	1.75	1.75	1.75	1.75	1.68	1.68	1.68
FII	0.06	0.07	0.08	0.08	0.08	0.08	0.07	0.1	0.1	0.09
DII	0.17	0.18	0.24	0.25	0.26	0.26	0.25	0.32	0.31	0.3
Public	0.22	0.21	0.15	0.13	0.12	0.12	0.15	0.23	0.25	0.27
Others	0	0	0	0	0	0	0	0	0	0
Total	2.22	2.22	2.22	2.22	2.22	2.22	2.22	2.34	2.34	2.34

Pros

Company has delivered good profit growth of 28% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 25%
Debtor days have improved from 86.25 to 61.91days.
Company has reduced debt.
Company is almost debt free.

Cons

Stock is trading at 3.7 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.